Introduction: Adults with T2D may have phenotypic subgroups; prior clustering analyses had limited measures of beta-cell function, islet autoimmunity, or both. We aimed to characterize T2D subgroups in Look AHEAD (Action for Health in Diabetes), a randomized trial of adults with clinically-diagnosed T2D and overweight/obesity.

Methods: In 3,952 participants, we measured islet autoantibodies (GADA, ZnT8A) and performed homeostatic model assessment v2 of beta cell function (HOMA2-B) and insulin resistance (HOMA2-IR) using fasting C-peptide. We applied k-means clustering using these measures plus age at T2D diagnosis, BMI, and HbA1c.

Results: We identified four subgroups (Figure): lower adiposity with good glycemic control (LA/GC, 42% of the sample), high adiposity with good glycemic control (HA/GC, 26%), poor glycemic control (PC, 30%) and islet autoimmunity (IA, 3%). The LA/GC subgroup had high HOMA2-B (median 73%) and low HOMA2-IR (median 2.4). HA/GC had the highest HOMA2-B (median 113%) and HOMA2-IR (median 3.8). The PC subgroup had low HOMA2-B (median 46%) and youngest T2D diagnosis. Only the IA subgroup had frequent islet autoimmunity (95% GADA+, 18% ZnT8A+) and had low HOMA2-B (median 55%). Insulin use was infrequent in LA/GC (9%) and HA/GC (4%), and common in PC (32%) and IA (41%).

Conclusions: Using clinically-available measures, we identified four distinct T2D subgroups with important physiologic differences.

Disclosure

S.J. Pilla: None. W.C. Knowler: None. A. Balasubramanyam: None. C.S. Hampe: None. S. Pietropaolo: None. D. Lin: None. A.M. Anderson: None. N. Zhao: None. Å. Lernmark: Advisory Panel; DiaMyd Medical AB, Stockholm, Sweden. M. Bancks: None. J. Clark: Advisory Panel; Boehringer-Ingelheim. N.M. Maruthur: Other Relationship; Johns Hopkins Health Care Solutions.

Funding

National Institute of Diabetes and Digestive and Kidney Diseases (R01DK126825, K23DK128572)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.